CA3179637A1 - Kinase inhibitors - Google Patents
Kinase inhibitors Download PDFInfo
- Publication number
- CA3179637A1 CA3179637A1 CA3179637A CA3179637A CA3179637A1 CA 3179637 A1 CA3179637 A1 CA 3179637A1 CA 3179637 A CA3179637 A CA 3179637A CA 3179637 A CA3179637 A CA 3179637A CA 3179637 A1 CA3179637 A1 CA 3179637A1
- Authority
- CA
- Canada
- Prior art keywords
- formula
- compound
- pharmaceutically acceptable
- isomer
- racemate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063033729P | 2020-06-02 | 2020-06-02 | |
| US202063033728P | 2020-06-02 | 2020-06-02 | |
| US202063033724P | 2020-06-02 | 2020-06-02 | |
| US63/033,724 | 2020-06-02 | ||
| US63/033,728 | 2020-06-02 | ||
| US63/033,729 | 2020-06-02 | ||
| US202163136593P | 2021-01-12 | 2021-01-12 | |
| US202163136587P | 2021-01-12 | 2021-01-12 | |
| US202163136577P | 2021-01-12 | 2021-01-12 | |
| US63/136,577 | 2021-01-12 | ||
| US63/136,587 | 2021-01-12 | ||
| US63/136,593 | 2021-01-12 | ||
| PCT/US2021/035509 WO2021247748A1 (en) | 2020-06-02 | 2021-06-02 | Kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3179637A1 true CA3179637A1 (en) | 2021-12-09 |
Family
ID=76601840
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3179637A Pending CA3179637A1 (en) | 2020-06-02 | 2021-06-02 | Kinase inhibitors |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US12448363B2 (https=) |
| EP (1) | EP4157446A1 (https=) |
| JP (2) | JP2023528421A (https=) |
| CN (1) | CN115867346B (https=) |
| AU (1) | AU2021283916A1 (https=) |
| CA (1) | CA3179637A1 (https=) |
| WO (1) | WO2021247748A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021398051A1 (en) | 2020-12-10 | 2023-07-27 | Principia Biopharma Inc. | Crystal form of tolebrutinib, preparation method therefor and use thereof |
| CN117915960A (zh) * | 2021-08-30 | 2024-04-19 | 百时美施贵宝公司 | 可用于布鲁顿酪氨酸激酶的pet成像的化合物 |
| WO2023227080A1 (zh) * | 2022-05-25 | 2023-11-30 | 百极弘烨(南通)医药科技有限公司 | 一种protac化合物、含其的药物组合物及其制备方法和应用 |
| JP2025521510A (ja) * | 2022-06-22 | 2025-07-10 | プリンシピア バイオファーマ インコーポレイテッド | 改変されたｂｔｋ阻害剤の作製方法 |
| CN116284025B (zh) * | 2023-02-20 | 2025-07-04 | 国科大杭州高等研究院 | 一种具有抗癌作用的螺杂环类化合物、药物组合物及其用途 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6509838B2 (ja) * | 2013-06-26 | 2019-05-08 | アッヴィ・インコーポレイテッド | Ｂｔｋ阻害薬としての一級カルボキサミド類 |
| EA034931B1 (ru) * | 2014-10-24 | 2020-04-08 | Бристол-Майерс Сквибб Компани | Индолкарбоксамидные соединения |
| SI3209651T1 (sl) * | 2014-10-24 | 2019-12-31 | Bristol-Myers Squibb Company | Derivati karbazola |
-
2021
- 2021-06-02 CN CN202180048117.5A patent/CN115867346B/zh active Active
- 2021-06-02 WO PCT/US2021/035509 patent/WO2021247748A1/en not_active Ceased
- 2021-06-02 EP EP21734730.1A patent/EP4157446A1/en active Pending
- 2021-06-02 AU AU2021283916A patent/AU2021283916A1/en active Pending
- 2021-06-02 JP JP2022574229A patent/JP2023528421A/ja active Pending
- 2021-06-02 US US18/007,705 patent/US12448363B2/en active Active
- 2021-06-02 CA CA3179637A patent/CA3179637A1/en active Pending
-
2025
- 2025-11-28 JP JP2025207773A patent/JP2026048716A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023528421A (ja) | 2023-07-04 |
| EP4157446A1 (en) | 2023-04-05 |
| CN115867346B (zh) | 2025-03-14 |
| WO2021247748A1 (en) | 2021-12-09 |
| US20230219923A1 (en) | 2023-07-13 |
| AU2021283916A1 (en) | 2023-01-05 |
| CN115867346A (zh) | 2023-03-28 |
| JP2026048716A (ja) | 2026-03-17 |
| US12448363B2 (en) | 2025-10-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12448363B2 (en) | Kinase inhibitors | |
| CN104144930B (zh) | 新的中氮茚化合物，它们的制备方法以及包含它们的药物组合物 | |
| CA3198885A1 (en) | Azaquinazoline pan-kras inhibitors | |
| JP2023506532A (ja) | Ｋｒａｓ突然変異型タンパク質阻害剤 | |
| JP6802263B2 (ja) | Ｔｙｋ２阻害剤およびその使用 | |
| AU2024219343A1 (en) | Antimicrobial organosilanes | |
| CA3166554A1 (en) | Benzamide containing compounds for modulating brg1- or brm-associated factors_________________________________________________ | |
| TW202142542A (zh) | 藉由軛合ｂｔｋ抑制劑與ｅ３連接酶配位基降解布魯頓氏酪胺酸激酶（ｂｔｋ）及其使用方法 | |
| CA3228369A1 (en) | Fused bicyclic heteroaryl compounds useful as nlrp3 inhibitors | |
| KR20240026521A (ko) | Shp2 억제제로서 유용한 신규한 헤테로환형 유도체 | |
| EP3394066A2 (en) | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | |
| US20240246977A1 (en) | Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and method of use | |
| AU2010275196A1 (en) | Fused aminodihydropyrimidone derivatives | |
| CA2875799A1 (en) | Pyrimidinyl tyrosine kinase inhibitors | |
| HK1214820A1 (zh) | 杂芳基吡啶酮和氮杂-吡啶酮酰胺化合物 | |
| US20260035367A1 (en) | PKC-Theta Modulators | |
| TW202517654A (zh) | 治療自體免疫疾病之雙環大環 | |
| EP3642204A1 (en) | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | |
| TW202340211A (zh) | 嘧啶雜環化合物、其製法與醫藥上的用途 | |
| AU2021219832B2 (en) | Dihydronaphthyridinone compound, and preparation method therefor and medical use thereof | |
| CA3174838A1 (en) | Kinase inhibitors | |
| JP2025521083A (ja) | ＨＰＫ１阻害剤としてのテトラヒドロピリド［３，４－ｄ］ピリミジン化合物 | |
| CA3204133A1 (en) | Indole derivatives as kinase inhibitors | |
| HK40080599A (en) | Dihydronaphthyridinone compound, and preparation method therefor and medical use thereof | |
| HK1234395B (zh) | 双环稠合的杂芳基或芳基化合物以及它们作为irak4拟制剂的用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| P22 | Classification modified |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED Effective date: 20241114 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241127 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241127 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241127 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20250530 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20250530 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250530 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250530 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250530 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250602 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250815 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250815 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250815 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250815 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250818 |
|
| R11 | Change to the name of applicant or owner or transfer of ownership requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R11-R127 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER RECORDAL REQUEST OR RESPONSE Effective date: 20250822 |
|
| R14 | Transfer of ownership recorded |
Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R14-R129 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250828 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250828 |
|
| R14 | Transfer of ownership recorded |
Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R14-R129 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250829 |